

The Cardiovascular Impact and Genetics of Pericardial Adiposity

Joel T Rämö^{1,2,3}, Shinwan Kany^{1,2,4}, Cody R Hou^{1,5}, Samuel F Friedman⁶, Carolina Roselli^{1,7}, Victor Nauffal^{8,1}, Satoshi Koyama¹, Juha Karjalainen^{3,9,10}, FinnGen, Mahnaz Maddah⁶, Aarno Palotie^{3,11,12,9,10}, Patrick T Ellinor^{*1,13,14,15}, James P Pirruccello^{*16,1,17,18}

*Jointly supervised

¹Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA, ²Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA, ³Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland, ⁴Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Hamburg, Germany, ⁵University of Minnesota Medical School, Minneapolis, Minnesota, USA, ⁶Broad Institute of MIT and Harvard, Cambridge, MA, USA, ⁷Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ⁸Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA, ⁹Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, ¹⁰Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA, ¹¹Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, ¹²Department of Neurology, Massachusetts General Hospital, Boston, MA, USA, ¹³Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, ¹⁴Cardiology Division, Massachusetts General Hospital, Boston, MA, USA, ¹⁵Harvard Medical School, Boston, MA, USA, ¹⁶Bakar Computation Health Sciences Institute, University of California San Francisco, San Francisco, CA, USA, ¹⁷Division of Cardiology, University of California San Francisco, San Francisco, California, USA, San Francisco, CA, USA, ¹⁸Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA

Short title: The Impact and Genetics of Pericardial Adiposity

Total word count: 6686

Word count excluding title page, abstract, references, tables, and legends: 3047

Corresponding author:

James P. Pirruccello, MD

Division of Cardiology

University of California San Francisco, 555 Mission Bay Blvd South, Box 3118

San Francisco CA 94158

james.pirruccello@ucsf.edu

Abstract

Background: While previous studies have reported associations of pericardial adipose tissue (PAT) with cardiovascular diseases such as atrial fibrillation and coronary artery disease, they have been limited in sample size or drawn from selected populations. Additionally, the genetic determinants of PAT remain largely unknown. We aimed to evaluate the association of PAT with prevalent and incident cardiovascular disease and to elucidate the genetic basis of PAT in a large population cohort.

Methods: A deep learning model was trained to quantify PAT area from four-chamber magnetic resonance images in the UK Biobank using semantic segmentation. Cross-sectional and prospective cardiovascular disease associations were evaluated, controlling for sex and age. A genome-wide association study was performed, and a polygenic score (PGS) for PAT was examined in 453,733 independent FinnGen study participants.

Results: A total of 44,725 UK Biobank participants (51.7% female, mean [SD] age 64.1 [7.7] years) were included. PAT was positively associated with male sex ($\beta = +0.76$ SD in PAT), age ($r = 0.15$), body mass index (BMI; $r = 0.47$) and waist-to-hip ratio ($r = 0.55$) ($P < 1 \times 10^{-230}$). PAT was more elevated in prevalent heart failure ($\beta = +0.46$ SD units) and type 2 diabetes ($\beta = +0.56$) than in coronary artery disease ($\beta = +0.22$) or AF ($\beta = +0.18$). PAT was associated with incident heart failure (HR = 1.29 per +1 SD in PAT [95% CI 1.17–1.43]) and type 2 diabetes (HR = 1.63 [1.51–1.76]) during a mean 3.2 (± 1.5) years of follow-up; the associations remained significant when controlling for BMI. We identified 5 novel genetic loci for PAT and implicated transcriptional regulators of adipocyte morphology and brown adipogenesis (*EBF1*, *EBF2* and *CEBPA*) and regulators of visceral adiposity (*WARS2* and *TRIB2*). The PAT PGS was associated with T2D, heart failure, coronary artery disease and atrial fibrillation in FinnGen (ORs 1.03–1.06 per +1 SD in PGS, $P < 2 \times 10^{-10}$).

Conclusions: PAT shares genetic determinants with abdominal adiposity and is an independent predictor of incident type 2 diabetes and heart failure.

Clinical Perspective

What is new?

- In a large, prospective and uniformly phenotyped cohort, pericardial adipose tissue was independently predictive of incident heart failure and type 2 diabetes when adjusted for body mass index.
- In contrast, pericardial adipose tissue was not independently predictive of atrial fibrillation.
- A genome-wide association study of pericardial adipose tissue identified five novel loci, implicating genes influencing adipocyte morphology, brown-like adipose tissue differentiation and abdominal adiposity.

What are the clinical implications?

- Pericardial adipose tissue accumulation may reflect a metabolically unhealthy adiposity phenotype similarly to abdominal visceral adiposity.

Non-standard Abbreviations and Acronyms

EAT: epicardial adipose tissue

GWAS: genome-wide association study

PAT: pericardial adipose tissue

PoPS: polygenic priority score

Introduction

The increased global burden of obesity as a leading cause and modifiable risk factor for cardiovascular diseases is well recognized¹. Not all obesity is alike, however, and the distribution of adipose tissue may be as important as its quantity. Abdominal adiposity, in particular, is associated with higher cardiovascular disease risk than subcutaneous adiposity^{1,2}. Similarly, ectopic fat storage surrounding the heart has been suggested to confer independent cardiovascular risk¹.

Pericardial adipose tissue (PAT) comprises epicardial adipose tissue (EAT)—located between the visceral pericardium and myocardium—and extrapericardial adipose tissue.^{3–5} In addition to the ectopic location of PAT within the thoracic cavity, the vascular supply of EAT derives from branches of the coronary arteries, similarly to the myocardium which is in immediate proximity to EAT with no separating fascia.⁶ EAT displays features of brown-like or beige adipose tissue and has been hypothesized to have a cardioprotective role via thermogenesis and supply of free fatty acids.⁷ However, multiple studies have suggested that EAT can also promote disease via secretion of pro-inflammatory and pro-fibrotic mediators⁸.

To date, more than 30 studies have reported the relation between PAT or EAT and a range of cardiovascular outcomes^{3,4,9–11}. Meta-analyses have also demonstrated associations of EAT with myocardial infarction, coronary revascularization, atrial fibrillation, and cardiac death¹¹. However, these studies have been limited in sample size and clinically heterogeneous as they have often been drawn from selected populations such as patients undergoing surgery or treatment for acute coronary syndromes.

The UK Biobank (UKB) is a large and deeply phenotyped population cohort with an ongoing cardiac magnetic resonance (CMR) imaging substudy.^{12,13} Coupled with advances in deep learning based annotation methods, this dataset enables the assessment of cardiovascular

traits such as PAT at scale. Genotyping of UKB participants allows for the simultaneous evaluation of the heritable determinants of PAT in a sample that is many times larger than previous cohorts.

In this study, we quantify PAT in 44,725 UKB participants by using a deep learning model. We first assess the cross-sectional and prospective disease associations of PAT with and without adjustment for BMI. We then evaluate the genetic determinants of PAT in UKB and the independent FinnGen study.

Methods

Study design

We included participants from UKB and the FinnGen study. Primary analyses examining pericardial adipose tissue were conducted in UKB, and secondary analyses examining a polygenic score for PAT were conducted in FinnGen (**Supplementary Figure 1**).

UKB is a deeply phenotyped prospective population-level cohort which recruited approximately 500,000 participants aged 40–69 in the UK between 2006–2010^{12,13}. A subset of participants within an imaging substudy underwent CMR with 1.5 T scanners (Magnetom Aera, Siemens Healthcare). This study has been conducted using the UKB Application Numbers #7089 and #17488 and was approved by the Mass General Brigham institutional review board (protocol 2003P001563).

FinnGen is a collection of prospective Finnish epidemiological and disease-based cohorts and hospital biobank samples linked to electronic health records (<https://www.finnngen.fi/en>).¹⁴ A total of 453,733 participants from the FinnGen Data Freeze 11 were included in this study.

Semantic segmentation of pericardial adipose tissue

Four-chamber images at random parts of the cardiac cycle from 250 randomly selected UKB CMR substudy participants were manually annotated by a physician (JTR). Segmentation maps were traced for pericardial adipose tissue and adjacent mediastinal structures including the cardiac chambers (**Supplementary Methods**). A total of 160 images were used for training, 40 images for validation and 50 images kept in a hold-out test set. A UNet based deep learning model from the fastai library v2.7.11 was constructed in PyTorch v1.13.1 using a ResNet50 encoder^{15,16}. The fine-tuned model was used to infer segmentation of pericardial adipose tissue

in the test set and all remaining UKB participants.^{15,16} Training parameters are detailed in the **Supplementary Methods**.

Epidemiologic analyses

In UKB, the following cardiovascular diseases were defined using a combination of International Classification of Diseases (ICD) codes, self-report, and procedure codes (**Supplementary Table 2**): atrial fibrillation of flutter (AF), coronary artery disease (CAD), heart failure (HF), stroke and type 2 diabetes (T2D). The associations of prevalent cardiovascular diseases with PAT were tested using linear regression models including PAT as the outcome and age and sex as covariates. The associations of PAT with incident diseases were tested using Cox proportional hazards models with time from imaging to diagnosis or censoring as the outcome and PAT (standard deviation scaled or percentile-stratified), sex, and age as the predictors. BMI was included as an additional covariate in adjusted models. Participants with the corresponding disease at the time of imaging were excluded from incident disease analyses. Follow-up time was censored on September 30, 2021.

In FinnGen, cardiovascular diseases were defined using a combination of International Classification of Diseases (ICD) codes from specialist inpatient, outpatient and cause-of-death registries, procedure codes, and medication reimbursement codes (**Supplementary Methods**).

Genotyping, imputation, and genetic quality control

We excluded UKB participants from genetic analyses if they had mismatch between reported and inferred sex, were outliers for heterozygosity or missingness, or had putative sex chromosome aneuploidy based on central quality control. Genotyped variants with MAF >1%, minor allele count >100, genotype missingness <5% and Hardy-Weinberg Equilibrium p-values

$>1 \times 10^{-15}$ were included in regenie step 1, and further UKB analyses were performed for imputed variants with INFO > 0.3 and minor allele frequency $> 1\%$.

Sample QC, genotyping and quality control for FinnGen samples has been reported previously.¹⁴ The FinnGen genotype imputation protocol is available at:

<https://dx.doi.org/10.17504/protocols.io.xbgfijw>.

Genome-wide association studies

We performed a genome-wide association study for PAT using the additive genetic model implemented in regenie v3.2.5¹⁷. In addition to PAT, we performed new GWAS for height, weight, BMI, and WHR in the CMR substudy participants to ensure comparability for genomic correlation analyses.

Heritability and genetic correlation analyses

Based on the summary statistics from the custom GWAS in the UKB imaging substudy, using LD Score Regression (LDSC) with HapMap3 variants and a European ancestry reference panel¹⁸, we calculated single nucleotide polymorphism heritability for PAT and genetic correlations between PAT and anthropometric measurements.

Polygenic score analyses

We estimated PGS weights for PAT using the PRSCs program in 'auto' mode based on a publicly available UKB European ancestry linkage disequilibrium panel and 1,117,404 HapMap3 variants¹⁹. PGSs were computed for all individuals in the FinnGen study. The associations of the PAT PGS with cardiovascular diseases were evaluated using logistic regression models with sex, age at the end of study follow-up or death, genomic principal components 1–5, and the

genotyping array as basic covariates. BMI was included as an additional covariate in adjusted models.

Additional computational and statistical software

Variant positions were lifted over from the GRCh37 build to the GRCh38 build for polygenic scoring in FinnGen using the UCSC liftOver tool⁹. All statistical analyses not otherwise specified were carried out in R (version 4.3.0)¹⁰.

Results

Semantic segmentation of PAT with deep learning

We began by manually annotating PAT in 200 four-chamber CMR images from randomly selected UKB participants at random phases of the cardiac cycle. We then fine-tuned a deep learning model based on ResNet50 to annotate PAT in the remaining participants. In a held out test set of 50 individuals, the model achieved a Dice score of 0.80 compared with a human annotator, similar to a recently reported model based on UKB CMR data.⁵ We further excluded 788 participants whose four-chamber images were not predicted to show at least 5 cm² of each cardiac chamber as a quality control step to remove misaligned or poor-quality images (**Supplementary Methods**). The area of PAT (in cm²) was computed in all remaining 44,475 participants.

The associations of PAT with demographic characteristics and anthropometric measures

In the study sample of 44,475 individuals, 51.7% of participants were female and the mean [SD] age was 64.1 [7.7] years (**Table 1**). The majority (96.7%) of the participants were of self-reported White ethnic background; participant characteristics by ethnic background are additionally reported in **Supplementary Table 1**. Men had on average more PAT compared with women (+0.78 SD units, $P < 3e-324$) (**Supplementary Figure 2**). Greater age was also associated with increased PAT ($r = 0.15$, $P = 9.3 \times 10^{-229}$).

We observed modest correlations with traditional anthropometric measures suggesting that PAT may convey additional information: PAT was associated with height ($r = 0.31$), weight ($r = 0.57$),

BMI ($r = 0.47$) and WHR ($r = 0.55$) ($P < 3 \times 10^{-324}$ for all). Simple linear estimates based on WHR tended to underestimate PAT particularly in participants with high WHR and PAT.

Prevalent cardiovascular diseases and PAT

We evaluated the associations of PAT with five prevalent cardiovascular diseases at the time of imaging (**Figure 2** and **Supplementary Table 3**). PAT was significantly elevated in individuals with prevalent T2D (+0.56 SD units in PAT, $P = 6.9 \times 10^{-133}$), HF (+0.46 SD, $P = 7.0 \times 10^{-19}$), CAD (+0.22 SD, $P = 1.3 \times 10^{-21}$), and AF (+0.18 SD, $P = 1.2 \times 10^{-2}$), but not in individuals with prevalent stroke (+0.09 SD, $P = 0.08$).

Predictive utility of PAT for incident cardiovascular diseases

In survival analyses, after excluding participants with prevalent diseases at the time of imaging, PAT as a continuous measurement was associated with incident T2D (HR 1.63 per +1 SD increment in PAT, 95% CI 1.51-1.76, $P = 7.2 \times 10^{-36}$), HF (HR 1.29, 95% CI 1.17–1.43, $P = 4.8 \times 10^{-7}$) and AF (HR 1.17, 95% CI 1.08–1.26, $P = 4.6 \times 10^{-5}$) (**Supplementary Figure 3** and **Supplementary Table 4**). We did not observe significant associations between PAT and incident coronary artery disease (HR 1.10, 95% CI 1.00-1.20, $P = 0.052$) or stroke (HR 1.12, 95% CI 0.99-1.27, $P = 0.063$). When including BMI as an additional covariate, PAT remained an independent predictor of incident T2D (HR 1.25, 95% CI 1.14–1.38, $P = 1.6 \times 10^{-6}$) and HF (HR 1.16, 95% CI 1.03–1.31, $P = 0.013$) (**Supplementary Figure 3**).

Recapitulating the patterns in analyses of PAT as a continuous measurement, in analyses stratified by PAT decile (**Figure 3**, **Supplementary Figures 4–5**, and **Supplementary Table 5**), those in the highest 10% vs. those in lowest 0-90% of PAT had significantly elevated risk of incident T2D (HR 3.14, 95% CI 2.50–3.95, $P = 1.5 \times 10^{-22}$), HF (HR 1.91, 95% CI 1.41–2.57, $P = 2.4 \times 10^{-5}$) and AF (HR 1.47, 95% CI 1.17–1.84, $P = 8.1 \times 10^{-4}$), but no significant elevation in risk

of of CAD (HR 1.33, 95% CI 0.99–1.77, $P = 0.057$) or stroke (HR 1.22, 95% CI 0.83-1.78, $P = 0.31$). Only the associations with incident T2D and HF remained significant when adjusted for BMI.

Genome-wide association study of PAT

We performed a genome-wide association study of PAT in 41,494 UKB participants who passed genotyping quality control, and identified seven loci at genome-wide significance ($P < 5e-8$) (**Figure 4, Supplementary Results and Supplementary Figure 7**). These included the two previously reported loci for PAT (with lead variants in or near *TRIB2* and *EBF1*) and five novel PAT loci with lead variants in or near *CDCA2*, *WARS2*, *IP6K1*, *C5orf67/ANKRD55*, and *PEPD* (**Supplementary Figure 6**). The single nucleotide polymorphism based heritability of PAT on the observed scale was 0.15 (SE 0.02).

We used the nearest protein-coding gene and Polygenic Priority Score (PoPS) approaches to prioritize likely causal genes in the seven association loci²⁰. The genes *WARS2*, *TRIB2*, *RBM6*, *MIER3*, *EBF1*, *EBF2*, and *CEBPA* were most strongly prioritized by PoPS in their respective loci (**Supplementary Table 6**). The nearest-gene approach and PoPS were concordant for *WARS2*, *TRIB2*, and *EBF1*.

Recapitulating correlations between measured PAT and many anthropometric variables, we also observed moderate genetic correlations between PAT and weight ($r_g = 0.48$, SE = 0.04, $P = 5.9 \times 10^{-30}$), BMI ($r_g = 0.50$, SE = 0.04, $P = 4.3 \times 10^{-30}$), and WHR ($r_g = 0.60$, SE = 0.05, $P = 2.7 \times 10^{-30}$) (**Supplementary Table 7**). In contrast, PAT was not genetically correlated with measured height ($r_g = 0.05$, $P = 0.31$).

Meta-analysis of genome-wide association studies of PAT

We additionally performed a meta-analysis of the UKB GWAS and a previously published smaller GWAS meta-analysis ($n = \text{up to } 12,204$)²¹. This meta-analysis of up to 53,698 participants was conducted based on p-values and effect direction due to the lack of effect size estimates in the previous meta-analysis that incorporated PAT indices from different imaging modalities (**Supplemental Methods**). In the new meta-analysis, we identified one novel locus (*CYP26B1*). The *CDCA2* locus did not reach significance, potentially because the three closely clustering variants driving the association in UKB were not included in the previously published meta-analysis and could not be analyzed together. (**Supplementary Figures 8–9** and **Supplementary Table 8**).

Predictive utility of a polygenic score for PAT

Lastly, we constructed a genome-wide polygenic score (PGS) for PAT using the PRS-CS method based on the summary statistics from the UKB GWAS. We subsequently evaluated the disease associations of the PAT PGS in 453,733 participants of the independent FinnGen study, sample characteristics of which are shown in **Supplementary Table 9**¹⁴. In logistic regressions, the PAT PGS was significantly associated with T2D, HF, CAD, AF or flutter, and stroke ($P < 0.004$ for all) (**Figure 5A** and **Supplementary Table 10**). These positive associations remained significant even when including BMI as an additional covariate ($P < 0.007$ for all) (**Figure 5B** and **Supplementary Table 10**).

Discussion

In this study, we examined the cardiovascular associations and genetic determinants of PAT in more than 40,000 individuals from a large, prospective and uniformly phenotyped cohort. These analyses enable several insights. We expand prior knowledge linking PAT as an independent predictor to HF and T2D. Genetic loci suggest that variation in PAT is influenced by regulators of adipocyte morphology, brown-like adipose tissue differentiation and abdominal adiposity. Our findings are consistent with PAT as a thoracic fat depot reflective of metabolically unhealthy adiposity independent of BMI.

Considerable interest has been focused on EAT as a potential local driver of cardiovascular disease. EAT has been hypothesized to contribute to AF by local secretion of profibrotic or inflammatory factors⁸. Paracrine or vasocrine release of cytokines and immune response factors from EAT to coronary diseases has been suggested to drive the development of atherosclerosis⁷. PAT—a superset that includes extrapericardial adipose in addition to EAT—has also been associated with visceral adipose tissue, as well as similar profiles of cardiovascular risk factors and metabolic syndrome^{5,22}, which raises the question of whether many of the observed disease associations may reflect global consequences of unhealthy visceral adiposity rather than more localized cardiac effects.

Here, we identify PAT to be most predictive of incident T2D and HF even after controlling for BMI. Our findings are in keeping with recently reported associations with incident T2D in 42,598 UKB participants and with incident heart failure with preserved ejection fraction in 6,785 participants of the Multi-Ethnic Study of Atherosclerosis (MESA)⁴. We observed a positive although non-significant association with incident CAD, which was attenuated when controlling for BMI. Significant independent predictive utility of PAT for incident CAD has previously been reported in a study of 6,814 MESA participants³. Finally, while we replicate an association

between PAT and prevalent AF⁹, PAT had no predictive utility for AF when controlling for BMI, in keeping with an analysis of 7,991 participants from MESA and Jackson Heart Study²³. In combination, these patterns of prospective associations are consistent with metabolically unhealthy adiposity.

We replicated two known genetic loci and identified five novel loci for PAT. Previously, a meta-analysis of 11,596 participants from heterogeneous imaging cohorts reported genetic loci containing *TRIB2* and *EBF1*, but provided no effect estimates for further assessments²¹. Here, the expansion of association loci allows several biological insights. A prominent finding is considerable genetic correlation and locus overlap with abdominal adiposity. Among genomic loci linked with PAT in this study, all have been previously associated with WHR²⁴. Four of seven loci (*IP6K1*, *CDCA2*, *C5orf67*, and *PEPD*) have been associated with visceral adipose tissue, while the *WARS2*, *TRIB2* and *EBF1* loci may be more specific to PAT²⁵. We also demonstrated that a polygenic score for PAT, when tested in the independent FinnGen study, recapitulated the disease-specific patterns observed in prospective UKB analyses, lending further validity to the phenotype definitions and suggesting that shared genetic variation affects both PAT and cardiovascular morbidity.

Prioritization of potentially causal genes in the association loci highlights interconnected biological pathways influencing PAT accumulation. On separate chromosomes, we prioritize the transcription factor encoding genes *EBF1* and *EBF2*. *EBF1* is a regulator of adipose cell morphology and lipolysis²⁶, and decreased levels of *EBF1* have been observed in white adipose tissue hypertrophy. *EBF2* is a promoter of brown-like / beige adipose cell differentiation²⁷. *CEBPA*, prioritized in another locus, encodes for the transcription factor CCAAT/enhancer binding protein alpha (C/EBP α), which shares binding sites with Peroxisome proliferator-activated receptor gamma (PPAR γ) and acts as a co-stimulator of adipogenesis and adipocyte differentiation^{28,29}. In a previously identified PAT locus, we also prioritize *TRIB2*, which is a

promoter of CCAAT/enhancer binding protein beta, which transactivates the expression of both C/EBP α and PPAR γ ³⁰. Finally, *WARS2* encodes the mitochondrial tryptophanyl-tRNA synthetase; a mutant *Wars2* mouse model exhibits reduced food intake, resistance to diet-induced obesity, and changes in relative visceral adiposity.³¹ Although many of the association loci overlap with more general measures of adiposity, they may represent a targeted subset of drivers of unhealthy adiposity, unlike many loci linked with BMI that may exert their effects via neuronal pathways and hunger regulation³².

The findings should be interpreted in the context of the study design. Firstly, in our quantitation of PAT we were not able to differentiate between epicardial and paracardial (extrapericardial) adipose tissue. Secondly, PAT quantitation was based on a single CMR slice. The relative localization of PAT surrounding the heart may carry added significance. Thirdly, the accuracy of PAT quantitation was not perfect. However, reduced accuracy is more likely to predispose to type II rather than type I error, and the identification of known and novel GWAS loci suggests that the increased sample size still outweighs reduced accuracy for genomic discovery. Fourth, participants in the UKB are healthier than the overall population³³, which may affect the external validity of disease risk estimates. Lastly, UKB participants were mostly of European ancestry, which may limit the generalizability of the findings to other ancestries.

In conclusion, we identify PAT as an independent predictor of incident T2D and HF. Individual variation in PAT is likely influenced by genes regulating abdominal adiposity, adipocyte morphology and brown-like adipogenesis. The intrathoracic accumulation of PAT may reflect a metabolically unhealthy adiposity phenotype similar to abdominal visceral adiposity.

References

1. Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge M-P, American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021;143:e984–e1010.
2. Agrawal S, Klarqvist MDR, Diamant N, Stanley TL, Ellinor PT, Mehta NN, Philippakis A, Ng K, Claussnitzer M, Grinspoon SK, Batra P, Khera AV. BMI-adjusted adipose tissue volumes exhibit depot-specific and divergent associations with cardiometabolic diseases. *Nat Commun*. 2023;14:266.
3. Ding J, Hsu F-C, Harris TB, Liu Y, Kritchevsky SB, Szklo M, Ouyang P, Espeland MA, Lohman KK, Criqui MH, Allison M, Bluemke DA, Carr JJ. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Clin Nutr*. 2009;90:499–504.
4. Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, Burke GL, McClelland RL, Arai AE, Bluemke DA. Pericardial Fat and the Risk of Heart Failure. *J Am Coll Cardiol*. 2021;77:2638–2652.
5. Ardissino M, McCracken C, Bard A, Antoniades C, Neubauer S, Harvey NC, Petersen SE, Raisi-Estabragh Z. Pericardial adiposity is independently linked to adverse cardiovascular phenotypes: a CMR study of 42 598 UK Biobank participants. *Eur Heart J Cardiovasc Imaging*. 2022;23:1471–1481.
6. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. *Nat Clin Pract Cardiovasc Med*. 2005;2:536–543.
7. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. *Nat Rev Endocrinol*. 2015;11:363–371.
8. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. *Nat Rev Cardiol*. 2022;19:593–606.
9. Thanassoulis G, Massaro JM, O'Donnell CJ, Hoffmann U, Levy D, Ellinor PT, Wang TJ, Schnabel RB, Vasan RS, Fox CS, Benjamin EJ. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. *Circ Arrhythm Electrophysiol*. 2010;3:345–350.
10. Antonopoulos AS, Antoniades C. The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles. *J Physiol*. 2017;595:3907–3917.
11. Chong B, Jayabaskaran J, Ruban J, Goh R, Chin YH, Kong G, Ng CH, Lin C, Loong S, Muthiah MD, Khoo CM, Shariff E, Chan MY, Lajeunesse-Trempe F, Tchernof A, Chevli P, Mehta A, Mamas MA, Dimitriadis GK, Chew NWS. Epicardial Adipose Tissue Assessed by Computed Tomography and Echocardiography Are Associated With Adverse Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. *Circ Cardiovasc*

Imaging. 2023;16:e015159.

12. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203–209.
13. Raisi-Estabragh Z, Harvey NC, Neubauer S, Petersen SE. Cardiovascular magnetic resonance imaging in the UK Biobank: a major international health research resource. *Eur Heart J Cardiovasc Imaging*. 2021;22:251–258.
14. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta Parolo P, Lehisto AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K, Rüeger S, Lemmelä S, Zhou W, Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S, Paajanen T, Llorens V, Gracia-Tabuenca J, Siirtola H, Reis K, Elnahas AG, Sun B, Foley CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas S, Bizaki-Vallaskangas A, Carpen O, Chen C-Y, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M, Finucane H, Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman ÅK, Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J, Jacob H, Jensen J-N, Joensuu H, John S, Julkunen V, Jung M, Junttila J, Kaarniranta K, Kähönen M, Kajanne R, Kallio L, Kälviäinen R, Kaprio J, FinnGen, Kerimov N, Kettunen J, Kilpeläinen E, Kilpi T, Klinger K, Kosma V-M, Kuopio T, Kurra V, Laisk T, Laukkanen J, Lawless N, Liu A, Longrich S, Mägi R, Mäkelä J, Mäkitie A, Malarstig A, Mannermaa A, Maranville J, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature*. 2023;613:508–518.
15. Paszke A, Gross S, Massa F, Lerer A, Bradbury J, Chanan G, Killeen T, Lin Z, Gimelshein N, Antiga L, Others. Pytorch: An imperative style, high-performance deep learning library. *Adv Neural Inf Process Syst* [Internet]. 2019;32. Available from: <https://proceedings.neurips.cc/paper/2019/hash/bdbca288fee7f92f2bfa9f7012727740-Abstract.html>
16. Howard J, Gugger S. Fastai: A Layered API for Deep Learning. *Information*. 2020;11:108.
17. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, Benner C, O'Dushlaine C, Barber M, Boutkov B, Habegger L, Ferreira M, Baras A, Reid J, Abecasis G, Maxwell E, Marchini J. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet*. 2021;53:1097–1103.
18. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Patterson N, Daly MJ, Price AL, Neale BM. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47:291–295.
19. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun*. 2019;10:1776.
20. Weeks EM, Ulirsch JC, Cheng NY, Trippe BL, Fine RS. Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. *MedRxiv* [Internet]. 2020; Available from: <https://www.medrxiv.org/content/10.1101/2020.09.08.20190561.abstract>

21. Chu AY, Deng X, Fisher VA, Drong A, Zhang Y, Feitosa MF, Liu C-T, Weeks O, Choh AC, Duan Q, Dyer TD, Eicher JD, Guo X, Heard-Costa NL, Kacprowski T, Kent JW Jr, Lange LA, Liu X, Lohman K, Lu L, Mahajan A, O'Connell JR, Parihar A, Peralta JM, Smith AV, Zhang Y, Homuth G, Kissebah AH, Kullberg J, Laqua R, Launer LJ, Nauck M, Olivier M, Peyser PA, Terry JG, Wojczynski MK, Yao J, Bielak LF, Blangero J, Borecki IB, Bowden DW, Carr JJ, Czerwinski SA, Ding J, Friedrich N, Gudnason V, Harris TB, Ingelsson E, Johnson AD, Kardina SLR, Langefeld CD, Lind L, Liu Y, Mitchell BD, Morris AP, Mosley TH Jr, Rotter JI, Shuldiner AR, Towne B, Völzke H, Wallaschofski H, Wilson JG, Allison M, Lindgren CM, Goessling W, Cupples LA, Steinhauser ML, Fox CS. Multiethnic genome-wide meta-analysis of ectopic fat depots identifies loci associated with adipocyte development and differentiation. *Nat Genet.* 2017;49:125–130.
22. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasani RS, O'Donnell CJ, Fox CS. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. *Circulation.* 2008;117:605–613.
23. Heckbert SR, Wiggins KL, Blackshear C, Yang Y, Ding J, Liu J, McKnight B, Alonso A, Austin TR, Benjamin EJ, Curtis LH, Sotoodehnia N, Correa A. Pericardial fat volume and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis and Jackson Heart Study. *Obesity.* 2017;25:1115–1121.
24. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, Yengo L, Ferreira T, Marouli E, Ji Y, Yang J, Jones S, Beaumont R, Croteau-Chonka DC, Winkler TW, GIANT Consortium, Hattersley AT, Loos RJF, Hirschhorn JN, Visscher PM, Frayling TM, Yaghootkar H, Lindgren CM. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet.* 2019;28:166–174.
25. Agrawal S, Wang M, Klarqvist MDR, Smith K, Shin J, Dashti H, Diamant N, Choi SH, Jurgens SJ, Ellinor PT, Philippakis A, Claussnitzer M, Ng K, Udler MS, Batra P, Khera AV. Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. *Nat Commun.* 2022;13:3771.
26. Gao H, Mejhert N, Fretz JA, Arner E, Lorente-Cebrián S, Ehlund A, Dahlman-Wright K, Gong X, Strömblad S, Douagi I, Laurencikiene J, Dahlman I, Daub CO, Rydén M, Horowitz MC, Arner P. Early B cell factor 1 regulates adipocyte morphology and lipolysis in white adipose tissue. *Cell Metab.* 2014;19:981–992.
27. Stine RR, Shapira SN, Lim H-W, Ishibashi J, Harms M, Won K-J, Seale P. EBF2 promotes the recruitment of beige adipocytes in white adipose tissue. *Mol Metab.* 2016;5:57–65.
28. Lin FT, Lane MD. CCAAT/enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program. *Proc Natl Acad Sci U S A.* 1994;91:8757–8761.
29. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell.* 1994;79:1147–1156.
30. Guo L, Li X, Tang Q-Q. Transcriptional regulation of adipocyte differentiation: a central role for CCAAT/enhancer-binding protein (C/EBP) β . *J Biol Chem.* 2015;290:755–761.
31. Mušo M, Bentley L, Vizor L, Yon M, Burling K, Barker P, Zolkiewski LAK, Cox RD, Dumbell

- R. A Wars2 mutant mouse shows a sex and diet specific change in fat distribution, reduced food intake and depot-specific upregulation of WAT browning. *Front Physiol.* 2022;13:953199.
32. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J 'an, Mägi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Zhao JH, Zhao W, Chen J, Fehrmann R, Hedman ÅK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Leach IM, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stančáková A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Ärnlöv J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Blüher M, Böhringer S, Bonnycastle LL, Böttcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Chen Y-DI, Clarke R, Daw EW, de Craen AJM, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature.* 2015;518:197–206.
33. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol.* 2017;186:1026–1034.

Appendices

Data availability

UK Biobank data are made available to researchers from research institutions with genuine research inquiries, following IRB and UK Biobank approval. GWAS summary statistics and polygenic score weights will be made available upon publication at the Broad Institute Cardiovascular Disease Knowledge Portal (<http://www.broadcvdi.org>). Pericardial adipose tissue measurements will be returned to the UK Biobank for use by any approved researcher. The Finnish biobank data can be accessed through the Fingenious® services (<https://site.fingenious.fi/en/>) managed by FINBB. Finnish Health register data can be applied for from Findata (<https://findata.fi/en/data/>).

Acknowledgements

We want to acknowledge the participants and investigators of UK Biobank and FinnGen studies. The following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (<https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx>), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank ([The Cardiovascular Impact and Genetics of Pericardial Adiposity](https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-</p></div><div data-bbox=)

[cohorts-and-arctic-biobank](#)). All Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (<https://finbb.fi/>) is the coordinator of BBMRI-ERIC operations in Finland.

Author contributions

JPP, PTE, AP, and JTR conceived of the study. JTR annotated images. JTR, JPP and CRH trained the deep learning models. JTR conducted bioinformatic analyses. CRH, SK, SFF, CR, VN, SK, JK, and MM, provided analysis support. JTR, JPP, PTE, and SK wrote the paper. All authors contributed to the analysis plan or provided critical revisions.

Sources of funding

Dr. Rämö was supported by a Fellowship from the Sigrid Jusélius Foundation. Dr. Pirruccello was supported by a Sarnoff Scholar Award and National Institutes of Health (NIH) grant K08HL159346. Dr. Kany was supported by the Walter Benjamin Fellowship from the Deutsche Forschungsgemeinschaft (521832260). Dr. Ellinor was supported by grants from the National Institutes of Health (R01HL092577, R01HL157635, R01HL139731), from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and from the European Union (MAESTRIA 965286). The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH. Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute.

Disclosures

Dr. Ellinor has received sponsored research support from Bayer AG, IBM Research, Bristol Myers Squibb and Pfizer; he has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. Dr. Pirruccello has served as a consultant for Maze Therapeutics and has received research support to the Broad Institute from IBM Research. The remaining authors report no disclosures.

Tables

Table 1. Characteristics of the study sample at the time of imaging

Characteristic	Women	Men	All
N	22972	21503	44475
Male sex (%)	0 (0.0)	21503 (100.0)	21503 (48.3)
Age (mean (SD))	63.4 (7.6)	64.8 (7.8)	64.1 (7.7)
Ethnicity			
White (%)	22246 (96.9)	20768 (96.6)	43014 (96.7)
Mixed ethnic background (%)	131 (0.6)	73 (0.3)	204 (0.5)
Asian or Asian British (%)	175 (0.8)	307 (1.4)	482 (1.1)
Black or Black British (%)	163 (0.7)	138 (0.6)	301 (0.7)
Chinese (%)	80 (0.3)	49 (0.2)	129 (0.3)
Other ethnic group (%)	125 (0.5)	101 (0.5)	226 (0.5)
Height, cm (mean (SD))	162.7 (6.2)	176.00 (6.6)	169.2 (9.3)
Weight, kg (mean (SD))	69.0 (13.1)	83.6 (13.4)	76.1 (15.1)
Body mass index, kg/m ² (mean (SD))	26.1 (4.7)	27.0 (3.9)	26.5 (4.4)
Waist circumference, cm (mean (SD))	82.7 (11.8)	94.3 (10.8)	88.3 (12.7)
Hip circumference, cm (mean (SD))	100.8 (9.8)	100.7 (7.4)	100.8 (8.7)
Waist-to-hip ratio (mean (SD))	0.82 (0.07)	0.94 (0.06)	0.88 (0.09)
PAT, cm ² (mean (SD))	21.8 (8.2)	30.6 (12.5)	26.0 (11.4)
Diabetes type 2 (%)	551 (2.4)	1128 (5.2)	1679 (3.8)
Heart failure (%)	76 (0.3)	240 (1.1)	316 (0.7)
Coronary artery disease (%)	300 (1.3)	1334 (6.2)	1634 (3.7)
Atrial fibrillation or flutter (%)	412 (1.8)	956 (4.4)	1368 (3.1)
Stroke (%)	167 (0.7)	300 (1.4)	467 (1.1)

Baseline characteristics at the time of imaging are shown for UK Biobank cardiac magnetic resonance imaging substudy participants with automated pericardial adipose tissue (PAT) area quantitation from four-chamber images. Anthropometric measurements were taken during the imaging visit. Prevalent diseases were ascertained based on a combination of self-reported data and International Classification of Diseases codes.


Table 2. Lead variants from the genome-wide association study of pericardial adipose tissue in UK Biobank

Chr	Position	rsID	NEA	EA	Nearest Gene	Nearest Gene Annotation	Top PoPS gene	EAF	Beta	SE	P
1	119699426	rs7530762	A	G	WARS2-AS1	intronic	WARS2	0.67	-0.62	0.075	2.4E-16
2	12882822	rs16350	ATC	A	TRIB2	UTR3	TRIB2	0.47	0.52	0.072	6.1E-13
3	49799046	rs577934120	CA	C	IP6K1	intronic	RBM6	0.45	0.42	0.075	1.8E-08
5	55794632	rs30351	G	A	C5orf67	intergenic	MIER3	0.74	-0.46	0.081	2.0E-08
5	158009651	rs553600342	A	AG	EBF1	intergenic	EBF1	0.24	-0.60	0.086	2.3E-12
8	25464670	rs73221948	G	T	CDCA2	intergenic	EBF2	0.29	-0.86	0.082	6.7E-26
19	34015904	rs41119	G	T	PEPD	intergenic	CEBPA	0.36	-0.42	0.076	3.7E-08

Variant positions are in the GRCh37 genome build. The nearest gene and the gene most strongly prioritized by the Polygenic Priority Score (PoPS) are shown for all lead variants. AF = allele frequency, Chr = chromosome, EA = effect allele, EAF = effect allele frequency, NEA = non-effect allele, PoPS = Polygenic Priority Score, SE = standard error.


Figures

Figure 1. Automated quantitation of pericardial adipose tissue in 44,475 UK Biobank participants




Pericardial adipose tissue (PAT) was quantified with deep learning in 44,475 UK Biobank participants based on a separate training and test set of 250 4-chamber cardiac magnetic resonance images. The associations between PAT and baseline characteristics (at the time of imaging) and incident diseases were evaluated. A genome-wide association study of PAT was conducted in 41,494 participants and the resulting summary statistics were used in gene prioritization, gene set enrichment and genetic correlation analyses. The disease associations of a polygenic score for PAT were evaluated in 453,733 participants of the FinnGen study. Magnetic resonance images are reproduced by kind permission of UK Biobank ©. Parts of the figures were generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.

Figure 2: The associations of prevalent cardiovascular diseases with pericardial adipose tissue




The associations of prevalent diseases with pericardial adipose tissue (PAT) were examined with linear regression models including the respective disease, age, and sex as predictors and PAT as the outcome. Each bar corresponds to the difference in PAT (in SD units) between those with prevalent disease and those without. Error bars correspond to positive 95% confidence intervals.

Figure 3: The associations of pericardial adipose tissue with incident cardiovascular diseases




Cumulative incidence curves for cardiovascular diseases are shown for participants stratified by PAT deciles at the time of imaging (top 10% vs others). The shaded areas correspond to 95% confidence intervals. Individuals with the corresponding disease at the time of imaging were excluded from the incident disease analyses. P-values were estimated using Cox Proportional hazards models with age and sex as additional covariates.

Figure 4: Manhattan plot of the genome-wide association study of pericardial adipose tissue in UK Biobank



A genome-wide association study of pericardial adipose tissue was performed in 41,494 UK Biobank participants. Each variant is plotted as a data point, with the corresponding $-\log_{10}(P)$ shown on the y-axis and the genomic position shown on the x-axis grouped by chromosomes. The genome-wide significance threshold ($P = 5 \times 10^{-8}$) is shown with a darker dashed line and a suggestive threshold ($P = 1 \times 10^{-5}$) is shown with a lighter dashed line. Genomic loci with at least one variant reaching genome-wide significance are labeled with the name of the nearest gene, and all variants within 500 kilobases of the lead variant are colored in a darker blue for visualization purposes. The y-axis is truncated to only show variants with a P-value ≤ 0.1 .

Figure 5: The predictive utility of a polygenic score for pericardial adipose tissue in FinnGen



A polygenic score (PGS) for pericardial adipose tissue (PAT) was constructed using PRS-CS based on summary statistics from the genome-wide association study of PAT in UK Biobank and subsequently applied to 453,733 participants in the FinnGen study. A. The associations of the PAT PGS with cardiovascular diseases were evaluated using logistic regression models with sex, age at the end of study follow-up or death, genomic principal components 1–5 and the genotyping array as basic covariates. B. The associations of the PAT PGS with cardiovascular

diseases were examined including body mass index (BMI) as an additional covariate. Odds ratios are shown per SD increment in PAT PGS.